Literature DB >> 29095502

Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.

Maria Kyrgiou1, Antonios Athanasiou, Ilkka E J Kalliala, Maria Paraskevaidi, Anita Mitra, Pierre Pl Martin-Hirsch, Marc Arbyn, Phillip Bennett, Evangelos Paraskevaidis.   

Abstract

BACKGROUND: The mean age of women undergoing local treatment for pre-invasive cervical disease (cervical intra-epithelial neoplasia; CIN) or early cervical cancer (stage IA1) is around their 30s and similar to the age of women having their first child. Local cervical treatment has been correlated to adverse reproductive morbidity in a subsequent pregnancy, however, published studies and meta-analyses have reached contradictory conclusions.
OBJECTIVES: To assess the effect of local cervical treatment for CIN and early cervical cancer on obstetric outcomes (after 24 weeks of gestation) and to correlate these to the cone depth and comparison group used. SEARCH
METHODS: We searched the following databases: Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library, 2017, Issue 5), MEDLINE (up to June week 4, 2017) and Embase (up to week 26, 2017). In an attempt to identify articles missed by the search or unpublished data, we contacted experts in the field and we handsearched the references of the retrieved articles and conference proceedings. SELECTION CRITERIA: We included all studies reporting on obstetric outcomes (more than 24 weeks of gestation) in women with or without a previous local cervical treatment for any grade of CIN or early cervical cancer (stage IA1). Treatment included both excisional and ablative methods. We excluded studies that had no untreated reference population, reported outcomes in women who had undergone treatment during pregnancy or had a high-risk treated or comparison group, or both DATA COLLECTION AND ANALYSIS: We classified studies according to the type of treatment and the obstetric endpoint. Studies were classified according to method and obstetric endpoint. Pooled risk ratios (RR) and 95% confidence intervals (CIs) were calculated using a random-effects model and inverse variance. Inter-study heterogeneity was assessed with I2 statistics. We assessed maternal outcomes that included preterm birth (PTB) (spontaneous and threatened), preterm premature rupture of the membranes (pPROM), chorioamnionitis, mode of delivery, length of labour, induction of delivery, oxytocin use, haemorrhage, analgesia, cervical cerclage and cervical stenosis. The neonatal outcomes included low birth weight (LBW), neonatal intensive care unit (NICU) admission, stillbirth, perinatal mortality and Apgar scores. MAIN
RESULTS: We included 69 studies (6,357,823 pregnancies: 65,098 pregnancies of treated and 6,292,725 pregnancies of untreated women). Many of the studies included only small numbers of women, were of heterogenous design and in their majority retrospective and therefore at high risk of bias. Many outcomes were assessed to be of low or very low quality (GRADE assessment) and therefore results should be interpreted with caution. Women who had treatment were at increased overall risk of preterm birth (PTB) (less than 37 weeks) (10.7% versus 5.4%, RR 1.75, 95% CI 1.57 to 1.96, 59 studies, 5,242,917 participants, very low quality), severe (less than 32 to 34 weeks) (3.5% versus 1.4%, RR 2.25, 95% CI 1.79 to 2.82), 24 studies, 3,793,874 participants, very low quality), and extreme prematurity (less than 28 to 30 weeks) (1.0% versus 0.3%, (RR 2.23, 95% CI 1.55 to 3.22, 8 studies, 3,910,629 participants, very low quality), as compared to women who had no treatment.The risk of overall prematurity was higher for excisional (excision versus no treatment: 11.2% versus 5.5%, RR 1.87, 95% CI 1.64 to 2.12, 53 studies, 4,599,416 participants) than ablative (ablation versus no treatment: 7.7% versus 4.6%, RR 1.35, 95% CI 1.20 to 1.52, 14 studies, 602,370 participants) treatments and the effect was higher for more radical excisional techniques (less than 37 weeks: cold knife conisation (CKC) (RR 2.70, 95% CI 2.14 to 3.40, 12 studies, 39,102 participants), laser conisation (LC) (RR 2.11, 95% CI 1.26 to 3.54, 9 studies, 1509 participants), large loop excision of the transformation zone (LLETZ) (RR 1.58, 95% CI 1.37 to 1.81, 25 studies, 1,445,104 participants). Repeat treatment multiplied the risk of overall prematurity (repeat versus no treatment: 13.2% versus 4.1%, RR 3.78, 95% CI 2.65 to 5.39, 11 studies, 1,317,284 participants, very low quality). The risk of overall prematurity increased with increasing cone depth (less than 10 mm to 12 mm versus no treatment: 7.1% versus 3.4%, RR 1.54, 95% CI 1.09 to 2.18, 8 studies, 550,929 participants, very low quality; more than 10 mm to 12 mm versus no treatment: 9.8% versus 3.4%, RR 1.93, 95% CI 1.62 to 2.31, 8 studies, 552,711 participants, low quality; more than 15 mm to 17 mm versus no treatment: 10.1 versus 3.4%, RR 2.77, 95% CI 1.95 to 3.93, 4 studies, 544,986 participants, very low quality; 20 mm or more versus no treatment: 10.2% versus 3.4%, RR 4.91, 95% CI 2.06 to 11.68, 3 studies, 543,750 participants, very low quality). The comparison group affected the magnitude of effect that was higher for external, followed by internal comparators and ultimately women with disease, but no treatment. Untreated women with disease and the pre-treatment pregnancies of the women who were treated subsequently had higher risk of overall prematurity than the general population (5.9% versus 5.6%, RR 1.24, 95% CI 1.14 to 1.34, 15 studies, 4,357,998 participants, very low quality).pPROM (6.1% versus 3.4%, RR 2.36, 95% CI 1.76 to 3.17, 21 studies, 477,011 participants, very low quality), low birth weight (7.9% versus 3.7%, RR 1.81, 95% CI 1.58 to 2.07, 30 studies, 1,348,206 participants, very low quality), NICU admission rate (12.6% versus 8.9%, RR 1.45, 95% CI 1.16 to 1.81, 8 studies, 2557 participants, low quality) and perinatal mortality (0.9% versus 0.7%, RR 1.51, 95% CI 1.13 to 2.03, 23 studies, 1,659,433 participants, low quality) were also increased after treatment. AUTHORS'
CONCLUSIONS: Women with CIN have a higher baseline risk for prematurity. Excisional and ablative treatment appears to further increases that risk. The frequency and severity of adverse sequelae increases with increasing cone depth and is higher for excision than it is for ablation. However, the results should be interpreted with caution as they were based on low or very low quality (GRADE assessment) observational studies, most of which were retrospective.

Entities:  

Mesh:

Year:  2017        PMID: 29095502      PMCID: PMC6486192          DOI: 10.1002/14651858.CD012847

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  56 in total

1.  Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study.

Authors:  Evangelos Paraskevaidis; Antonios Athanasiou; Maria Paraskevaidi; Evripidis Bilirakis; Georgios Galazios; Emmanuel Kontomanolis; Konstantinos Dinas; Aristotelis Loufopoulos; Maria Nasioutziki; Ioannis Kalogiannidis; Apostolos Athanasiadis; Alexios Papanikolaou; Anastasia Vatopoulou; Gregorios Grimbizis; Dimitrios Tsolakidis; Alexandros Daponte; George Valasoulis; Stella Gritzeli; Georgios Michail; Georgios Adonakis; Minas Paschopoulos; Orestis Tsonis; Maria-Eugenia Anaforidou; Anna Batistatou; Maria Kyrgiou
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers.

Authors:  Megan A Clarke; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2018-05-24       Impact factor: 5.284

3.  Healing pattern of the cervical stroma following cold coagulation treatment for cervical intraepithelial neoplasia: A case report.

Authors:  Dimitrios Papoutsis; Joanna Williams; Martyn Underwood; William Parry-Smith
Journal:  Oncol Lett       Date:  2022-01-14       Impact factor: 2.967

Review 4.  The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes.

Authors:  Susan Yuill; Louiza S Velentzis; Megan Smith; Sam Egger; C David Wrede; Deborah Bateson; Marc Arbyn; Karen Canfell
Journal:  Hum Vaccin Immunother       Date:  2021-10-03       Impact factor: 4.526

5.  Safety of Conservative Management of High-Grade Squamous Intraepithelial Lesion in Women Under 30 Years Old.

Authors:  Mariana K Bonas; Michelle G Discacciati; Hisa M Videira; Lucas A Cavalcante; Julio C Teixeira; Diama B Vale
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-06-22

6.  Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study.

Authors:  Rikke Kamp Damgaard; David Jenkins; Maurits Nc de Koning; Wim Gv Quint; Mark H Stoler; John Doorbar; Johnny Kahlert; Patti E Gravitt; Torben Steiniche; Lone Kjeld Petersen; Anne Hammer
Journal:  BMJ Open       Date:  2022-07-06       Impact factor: 3.006

7.  Analysis of the agreement between colposcopic impression and histopathological diagnosis of cervical biopsy in a single tertiary center of Chengdu.

Authors:  Juan Li; Wei Wang; Ping Yang; Jing Chen; Qianling Dai; Ping Hua; Dandan Liu
Journal:  Arch Gynecol Obstet       Date:  2021-03-08       Impact factor: 2.344

8.  Classification of high-grade cervical intraepithelial neoplasia by p16ink4a , Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management.

Authors:  Frederique J Vink; Stèfanie Dick; Daniëlle A M Heideman; Lise M A De Strooper; Renske D M Steenbergen; Birgit I Lissenberg-Witte; Arno Floore; Jesper H Bonde; Anja Oštrbenk Valenčak; Mario Poljak; Karl U Petry; Peter Hillemanns; Nienke E van Trommel; Johannes Berkhof; Maaike C G Bleeker; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2021-05-11       Impact factor: 7.396

9.  Use of extended HR-HPV Genotyping in improving the Triage Strategy of 2019 ASCCP recommendations in Women with positive HR-HPV diagnosis and Simultaneous LSIL Cytology Results.

Authors:  Huifeng Xue; Hangjing Gao; Jinwen Zheng; Yaojia Chen; Jiancui Chen; Diling Pan; Binhua Dong; Pengming Sun
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

Review 10.  Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Authors:  Marc Arbyn; Lan Xu; Cindy Simoens; Pierre Pl Martin-Hirsch
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.